For the quarter ending 2025-09-30, KZR had $4,568K increase in cash & cash equivalents over the period. -$9,830K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,227 | -30,260 |
| Depreciation and amortization | 227 | 494 |
| Stock-based compensation | 2,136 | 5,200 |
| Amortization of premiums and discounts on marketable securities | 494 | 1,275 |
| Amortization of debt discount and issuance costs and other non-cash interest | 37 | 201 |
| Impairment loss of right-of-use asset | 0 | 0 |
| Reclassification of currency translation loss | 282 | - |
| Gain on disposition of fixed assets | 4 | - |
| Prepaid expenses and other current assets | 432 | -1,390 |
| Other assets | -674 | -1,741 |
| Accounts payable, accrued and other current liabilities | -426 | -6,322 |
| Operating lease assets and liabilities | 603 | 1,154 |
| Net cash used in operating activities | -9,830 | -29,985 |
| Purchases of property and equipment | 0 | 8 |
| Proceeds from sale of fixed assets | 9 | - |
| Purchases of marketable securities | 14,297 | 28,334 |
| Maturities of marketable securities | 30,000 | 53,481 |
| Net cash provided by investing activities | 15,712 | 25,139 |
| Repayment of loan principal | 1,305 | 2,608 |
| Proceeds from issuance of common stock under employee stock incentive plans | 0 | 35 |
| Net cash (used in) provided by financing activities | -1,305 | -2,573 |
| Effect of exchange rate changes on cash and cash equivalents | -9 | 37 |
| Net decrease in cash and cash equivalents | 4,568 | -7,382 |
| Cash and cash equivalents at beginning of period | 41,749 | - |
| Cash and cash equivalents at end of period | 38,935 | - |
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)